Dino Mehic
dinomehic.bsky.social
Dino Mehic
@dinomehic.bsky.social
MD PhD | Physician Scientist at Medical University of Vienna | Thrombosis and Haemostasis | Hematology
Reposted by Dino Mehic
🌟 #ECTH2025 is just around the corner! 🌟
Join us in Prague to explore the latest discoveries in #thrombosisandhaemostasis in a beautiful place rich in culture.
🔗 Register here to secure early bird rates: www.ecth.org/registration/

Curious about CzechFunFact #2?

#ECTH2025 #ECTHJAB #CzechFunFacts
June 11, 2025 at 10:25 PM
Reposted by Dino Mehic
So inspiring to see the #ISTHearlycareer leaders play important roles to advance many @isth.org program. Learn more about ISTH #SSC Co-Chairs and their important contributions:
➡️Gael Marrow
➡️@dinomehic.bsky.social
➡️@aaron-iding.bsky.social
➡️Cheryl Maier
Read more here: bit.ly/3XOmNCI
April 9, 2025 at 2:29 PM
Very interesting data on the role of fibrin film in health and disease by @fibrin-fraser.bsky.social @ GTH2025 in Lausanne
February 21, 2025 at 10:35 AM
At this years #GTH2025 in Lausanne everything is about ARTE - advances - research - technology and education!
February 19, 2025 at 7:57 AM
Interesting case-report from Germany on a successful treatment of multi-refractory primary immune thrombocytopenia using CD19 CAR T-cell therapy. Could this be a therapeutic option for multi-refractory ITP? www.thelancet.com/journals/lan...
January 3, 2025 at 11:01 PM
🎄🎄🎄
End-of-the-year get-together at the Christmas dinner/party of our Thrombosis and Haemostasis Research Group in Vienna.
Happy, proud & grateful what the team has achieved this year with many contributions to science & education.
Thank you to each team member - looking forward to continue our work!
December 26, 2024 at 8:02 PM
Reposted by Dino Mehic
Excellent short commentary in the journal Blood about the prospective Austrian study examining bleeding in cancer patients. The rates of bleeding observed were higher than the placebo arms of anticoagulation in cancer studies. #Cancer #bleeding
November 28, 2024 at 7:34 PM
Reposted by Dino Mehic
Did anyone else get excited to see this Late Breaking Clinical Trial appear for #ASH24? Really important data on low- vs. standard-dosing DOACs for long-term treatment of VTE. However, results are complex... will they change practice?
ash.confex.com/ash/2024/web...
Paper: Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence
ash.confex.com
November 25, 2024 at 8:07 PM